HSBC Small Cap Fund
The Scheme will primarily be a diversified equity fund which will invest predominantly in small cap stocks to generate long term capital appreciation.
Growthvine rating: 3/5 — ranked #17 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹80.89 (as of 2026-10-23) |
|---|
| AUM | ₹18,513 Cr |
|---|
| Expense ratio | 1.42% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Venugopal Manghat |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| Sharpe ratio | 0.41 |
|---|
| Standard deviation | 21.95% |
|---|
| Max drawdown | −27.33% |
|---|
| Alpha | 0.73 |
|---|
| Beta | 0.98 |
|---|
Over 5 years, captured 91.3% of NIFTY Smallcap 250's upside and 85.4% of its downside.
Market cap allocation
| Large cap | 1.3% |
|---|
| Mid cap | 21.7% |
|---|
| Small cap | 77.0% |
|---|
Concentration
| Top 5 holdings | 11.1% |
|---|
| Top 10 holdings | 20.7% |
|---|
| Total holdings | 108 |
|---|
| Index overlap | 27.3% |
|---|
| Active share | 72.7% |
|---|
Top holdings
- Apar Industries Ltd — 2.7%
- Sai Life Sciences Limited — 2.2%
- Engineers India Ltd. — 2.2%
- Karur Vysya Bank Ltd. — 2.0%
- WELSPUN LIVING LIMITED — 2.0%
- PNB Housing Finance Limited — 2.0%
- Vijaya Diagnostic Centre Limited — 1.9%
- Federal Bank Ltd. — 1.9%
- Navin Fluorine International Limited — 1.9%
- Neuland Laboratories Limited. — 1.9%
Top sectors
- Industrial Products — 16.0%
- Banking & Financial — 14.0%
- Pharma & Biotech — 9.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 3.2% | Q3 | #19 of 34 |
| 2025 | −11.5% | Q4 (Bottom) | #28 of 30 |
| 2024 | 28.5% | Q2 | #8 of 28 |
| 2023 | 46.1% | Q2 | #8 of 24 |